Collaboration Agreements - Additional Information (Details)
 1 Months Ended 12 Months Ended
Dec. 03, 2021
USD ($)
Oct. 01, 2021
Jun. 30, 2021
USD ($)
Jun. 17, 2020
USD ($)
Target
Jan. 02, 2019
USD ($)
Candidate
Target
Obligation
Apr. 30, 2021
Target
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 23, 2020
USD ($)
Collaboration Agreements [Line Items]                  
Number of performance obligations | Obligation         8        
Total collaboration revenue             $ 22,935,000 $ 2,915,000  
Revenue recognized was previously classified as, Deferred revenue, net of current portion             19,048,000 641,000  
Deferred revenue             43,649,000    
Up-front and non-refundable cash payments received             66,000,000.0    
Deferred revenue             12,963,000 5,281,000  
Collaboration and License Agreement | Jazz Pharmaceuticals Ireland Limited                  
Collaboration Agreements [Line Items]                  
Number of oncogene targets | Target         5        
Number of targets | Target         4        
Number of oncogene targets discontinue work | Target           1      
Number of clinical trial candidates | Candidate         2        
Number of remaining candidates | Candidate         3        
Additional milestone payment related to regulatory approval of product         $ 20,000,000.0        
Up-front payment         56,000,000.0        
Preclinical development milestone payments eligible to receive         20,000,000.0        
Collaboration target payment receivable due upon second initiation         10,000,000.0        
Milestone payments eligible to receive         $ 200,000,000.0        
Notice period for termination of agreement         180 days        
Collaboration arrangement transaction price measured based on non-refundable and non creditable up-front payment             56,000,000.0    
Variable consideration payable included in transaction price at inception             0    
Remaining consideration comprised solely of transaction price                 $ 55,000,000.0
Changes in estimate of variable consideration             0    
Remaining deferred revenue recognized             10,900,000    
Total collaboration revenue     $ 2,800,000       11,300,000 600,000  
Deferred revenue             43,700,000 55,000,000.0  
Deferred revenue             12,600,000    
Collaboration and License Agreement | Jazz Pharmaceuticals Ireland Limited | Research and Development                  
Collaboration Agreements [Line Items]                  
Cost associated with obligations under arrangement             2,500,000 3,300,000  
Collaboration and License Agreement | Jazz Pharmaceuticals Ireland Limited | Development and Commercialization License and Associated Research Services | ASU 2014-09                  
Collaboration Agreements [Line Items]                  
Option to include additional target additional cost         $ 0        
Replacement target additional cost         0        
Collaboration and License Agreement | Jazz Pharmaceuticals Ireland Limited | Research Services | ASU 2014-09                  
Collaboration Agreements [Line Items]                  
Option to request additional research program additional cost         0        
Collaboration and License Agreement | Jazz Pharmaceuticals Ireland Limited | Non-GLP Toxicology Studies | ASU 2014-09                  
Collaboration Agreements [Line Items]                  
Per backup development candidate cost upon exercise         $ 0        
Collaboration and License Agreement | Jazz Pharmaceuticals Ireland Limited | License and Services                  
Collaboration Agreements [Line Items]                  
Performance obligation unsatisfied             39,600,000 50,900,000  
Collaboration and License Agreement | Jazz Pharmaceuticals Ireland Limited | All Other Services                  
Collaboration Agreements [Line Items]                  
Performance obligation unsatisfied             4,100,000 4,100,000  
Sarepta Research Agreement                  
Collaboration Agreements [Line Items]                  
Up-front payment       $ 7,000,000.0          
Milestone payments eligible to receive       $ 192,500,000          
Total collaboration revenue $ 7,000,000.0           11,600,000 2,300,000  
Revenue recognized was previously classified as, Deferred revenue, net of current portion $ 7,000,000.0                
Deferred revenue             0 7,700,000  
Research agreement period   2 years   2 years          
Number of agreed targets | Target       5          
Effective contract termination date   Dec. 03, 2021              
Term of option exercise       Jun. 17, 2022          
Extended term of option exercise       Dec. 17, 2022          
Up-front and non-refundable cash payments received       $ 10,000,000.0          
Up-front research services prepayment       3,000,000.0          
Collaboration arrangement obligated to remit option exercise payment       12,500,000          
Collaboration arrangement obligated options exercised       62,500,000          
Sarepta Research Agreement | Research and Development                  
Collaboration Agreements [Line Items]                  
Cost associated with obligations under arrangement             $ 4,600,000 2,300,000  
Sarepta Research Agreement | ASU 2014-09                  
Collaboration Agreements [Line Items]                  
Up-front payment       7,000,000.0          
Up-front research services prepayment       3,000,000.0          
Aggregate transaction price       18,000,000.0          
Estimation of cost reimbursements       $ 8,000,000.0          
Sarepta Research Agreement | All Other Services                  
Collaboration Agreements [Line Items]                  
Performance obligation unsatisfied               7,000,000.0  
Sarepta Research Agreement | Research License and Services                  
Collaboration Agreements [Line Items]                  
Performance obligation unsatisfied               $ 8,700,000